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Two patients, returning to the Netherlands from pil-
grimage in Medina and Mecca, Kingdom of Saudi 
Arabia, were diagnosed with Middle East respiratory 
syndrome coronavirus (MERS-CoV) infection in May 
2014. The source and mode of transmission have not 
yet been determined. Hospital-acquired infection and 
community-acquired infection are both possible.
On 13 May 2014, a Dutch patient, returning to the 
Netherlands from pilgrimage in Medina and Mecca, 
Kingdom of Saudia Arabia, was diagnosed with Middle 
East respiratory syndrome coronavirus (MERS-CoV) 
infection, followed by diagnosis of a second patient, 
belonging to the same tour group, the day after. Here we 
describe the two cases and the public health response. 
The case definition that is used in the Netherlands is 
outlined in the Box. 
Case 1 
A 70 year-old male patient with cardiovascular co-
morbidities and diabetes mellitus was diagnosed with 
MERS-CoV infection on 13 May. He had been in Medina 
since 26 April, together with a group of 30 other trav-
ellers. During the whole journey, he shared the hotel 
rooms with his adult son and another family member 
(see below). On 29 April, while still in good health, he 
accompanied his son to two hospitals (Hospitals 1 and 
2), both in Medina, as the son had a minor health prob-
lem unrelated to MERS CoV. He spent 45 minutes in the 
waiting room, reportedly among many coughing peo-
ple in Hospital 1. On 1 May, he experienced diarrhoea, 
nausea and anorexia and felt feverish, but had no res-
piratory complaints. The diarrhoea remitted after lop-
eramide treatment. On 4 May, the group of travellers, 
including the patient, continued to Mecca. On 5 May, 
he was seen at Hospital 3 for malaise, again diarrhoea, 
anorexia. On 7 May, he was physically examined at 
Hospital 4 and dismissed after three hours of obser-
vation and intravenous cefuroxime. During the flight 
home to the Netherlands, on 10 May, the patient’s 
condition deteriorated: on arrival, he visited a Dutch 
hospital, presenting with cough and dyspnoea. Apart 
from a temperature of 38.2 °C ( after paracetamol 37.3 
°C, both measured in the ear), the physical examina-
tion was normal. Laboratory results showed a mild 
leuco- and lymphopenia, a C-reactive protein level of 
72 mg/L (norm: 0–8 mg/L) and slightly elevated levels 
of troponin T (0.034 µg/L; norm: <0.014 µg/L) and cre-
atinine (123 µmol/L; norm: 65–115 µmol/L). In 2012, the 
patient had had a tropinin T level of 0.010, with a sta-
ble and mild pre-existing chronic kidney disease with 
a creatinine level of 113–136 µmol/L. He was admitted 
to the cardiology ward with possible cardiovascular 
disease and isolation precautions were taken because 
of an unspecified infection. Reassessment of his chest 
X-ray the next day revealed an infiltrate. On 13 May, 
MERS-CoV infection was confirmed. Lung examination 
then revealed extensive crepitations and a chest-X-ray 
showed bilateral infiltrates. Myocarditis was ruled out 
by magnetic resonance imaging of the heart. He is cur-
rently recovering. 
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Case 2
During contact investigations, the 73 year-old sister of 
the patient (with cardiovascular co-morbidities, chronic 
kidney disease and diabetes mellitus) was found to be 
symptomatic and was diagnosed with MERS-CoV infec-
tion late in the night of 14 May. She had shared the 
hotel rooms during the entire trip with Case 1 and his 
adult son and developed symptoms on 5 May, having 
diarrhoea, feeling feverish (not measured, slight cough 
and slight dyspnoea. She had not sought medical care 
in Saudia Arabia. During a routine check-up by a gen-
eral practitioner in the Netherlands on 12 May, she did 
not have a fever, but a slight cough and extensive crep-
itations of both lungs. The general practitioner consid-
ered MERS-CoV infection, because of the recent travel 
history, but did not arrange for diagnostic tests to be 
carried out as the patient did not meet the definition 
of a suspected case (no fever, no acute respiratory dis-
tress syndrome). Following contact tracing for Case 1, 
samples were taken from her and she was diagnosed 
with MERS-CoV infection. Following the diagnosis, she 
was admitted to hospital on 15 May where a chest X-ray 
showed bilateral infiltrates. She is currently recovering. 
The travel route and a timeline of events for the two 
cases are shown (Figures 1 and 2).
Laboratory findings
Diagnosis of MERS-CoV infection was done using 
an internally controlled real-time reverse transcrip-
tion (RT)-PCR using nucleic acid extracts from throat 
swabs and published upE, N-gene and ORF1A prim-
ers [1,2] according to International Organization for 
Standardization (ISO) guidelines (ISO 15189:2003) [3]. 
The results were independently confirmed in two labo-
ratories, Erasmus MC in Rotterdam and the National 
Institute for Public Health and the Environment (RIVM) 
in Bilthoven, the Netherlands [4].  During extensive fol-
low-up sampling, MERS-CoV RNA was detected in throat 
swabs, serum and stools from both cases (Table). Case 
2 had detectable MERS-CoV RNA in a throat swab, but 
not in a nose swab (data not shown), both collected on 
day 0 (date of diagnosis). Follow-up of the patients is 
still ongoing. 
Throat swabs of both cases tested on day 0 (the day 
MERS-CoV was diagnosed) were negative by real-time 
RT-PCR for 15 other respiratory viruses (influenza A 
and B virus, respiratory syncytial virus types A and B, 
human metapneumovirus, HCoV-OC43, -229E, -NL63, 
rhinovirus, parainfluenza type 1, 2, 3, 4, adenovirus 
and bocavirus) as described elsewhere [5].
To characterise the virus strain, partial genome 
sequencing was done as described by Haagmans et 
al. [2]. Sequence analysis was carried out directly from 
clinical specimens (respiratory samples) of both cases, 
yielding in total 4 kb of genome sequence for Case 1 
and 2.4 kb for Case 2 (GenBank accession numbers 
KJ858495-KJ858500). The sequences were nearly iden-
tical (one nucleotide difference) and were distinct from 
Box
Middle East respiratory syndrome coronavirus (MERS-
CoV) case definition and definition of contacts used in the 
Netherlands
Suspected case
Patient with a severe acute respiratory tract infection with:
 – fever (≥38 °C)a,b and respiratory symptoms
AND
 – an infiltrate on an X-ray of the lungs, or acute respiratory 
distress syndrome
AND
 – travel history to an areac with notified MERS-CoV (<14 days 
before the onset of symptoms) 
OR
a patient who has been in contact with a confirmed symptomatic 
MERS-CoV case (<14 days before onset of symptoms)
OR
a patient who is part of a cluster of two or more epidemiologically 
linked cases with an unknown causal agent for whom admission 
to an intensive-care unit is necessary, within a period of 14 days, 
irrespective of travel history.
Confirmed case
A person with laboratory-confirmation of MERS-CoV infection 
(positive PCR, with or without confirmation by sequencing).
Close contact
 – face-to-face contact (>15 minutes) within a household or 
other closed setting 
OR
– a healthcare worker, providing clinical or personal care to a 
confirmed, symptomatic case or who was in the same room as 
a patient during an aerosol-generating procedure and who did 
not wear adequate personal protection 
– flight contact (seated in the same row or three rows in front 
of/behind a confirmed case.
Protected hospital contact
A healthcare worker, providing clinical or personal care to a 
confirmed, symptomatic case or who was in the same room as a 
patient during an aerosol-generating procedure and who did wear 
adequate personal protection. 
Contacts were requested to measure their temperature twice 
daily and report any episode of fever, cough, dyspnoea or 
diarrhoea for a period of 14 days post exposure. Close contacts 
were approached on a daily basis by the regional public health 
service. Protected hospital contacts were expected to report 
health complaints without having daily follow-up. Throat and 
serum samples of all contacts were examined on days 7 and 14 
(molecular testing) and 7 and 21 (serology) post exposure.
a Or a feverish feeling in elderly people, as they do not always 
develop fever. 
b An immunocompromised patient with a severe infection of any 
origin, who meets the epidemiological criteria, i.e. contact with 
a MERS-CoV confirmed case or stay in area with MERS-CoV 
notified cases, both <14 days before onset of symptoms.
c Since 1 April 2013, the Middle East, especially Jordan, Saudi 
Arabia, Qatar and the United Arab Emirates. 
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recently published sequences from a hospital cluster 
in Jeddah, Saudi Arabia] [6]. However, the sequences 
clustered with that from a recently diagnosed traveller 
returning to the United States (US) from Saudi Arabia 
[7] (Figure 2). 
Visits while in Saudi Arabia
The group of 31 people travelled together in Saudi 
Arabia, used private transport, went on a joint trip to 
several mosques around Medina and spent the other 
days individually performing religious rituals in differ-
ent mosques, visiting local markets and eating in dif-
ferent establishments. On 3 May, 12 members of the 
group (not including the two cases) visited Wadi-e-Jinn 
near Medina and came across a dromedary camel herd 
with a few farmers who created a temporary shelter. 
All 12 drank raw dromedary milk, offered to them by 
the farmer. The group did not take any animal products 
back for Cases 1 and 2. 
Contact investigations
A total of 78 close contacts were identified (among 
which were the travel group, relatives and flight con-
tacts) and monitored as described in the Box. All 
healthcare workers were well protected. The number 
of flight contacts was limited (n=18) due to the fact 
that both cases were seated together on the last row 
in the plane. All flight contacts were Dutch residents. 
The monitoring period has come to an end for 70 close 
contacts and will be finalised by 29 May for the last 
group (n=8). No additional cases of MERS-CoV infec-
tion have been found during this period. All molecular 
(throat swabs) and serological samples taken from the 
contacts have been negative for MERS-CoV so far. The 
testing will be completed by mid-June. 
Background
MERS-CoV was first recognised in 2012, when it caused 
severe pneumonia in a patient from Saudi Arabia [8]. 
Since then, cases have been notified from several 
countries in the Arabian peninsula, with occasional 
exportation through infected travellers [9]. The exact 
epidemiology of the infection remains to be deter-
mined, but contact with animals, particularly drom-
edary camels, as well as contact with patients with 
MERS-CoV infection are risk exposures [10,11] A recent 
upsurge in the number of primary cases in the commu-
nity in the Kingdom of Saudi Arabia, possibly associ-
ated with the weaning season in dromedary cases, has 
been amplified by person-to-person transmission due 
to poor hospital hygiene measures in some hospitals 
in the Kingdom of Saudi Arabia [10,11]. 
Discussion 
There are several options for the possible source of the 
infection of the two Dutch cases: Case 1 could have 
been infected during the hospital visit of his child on 
29 April, after which he infected Case 2. Alternatively, 
both could have been exposed to a common, as yet 
unknown, source in Medina. Thirdly, each case could 
have been infected through different sources (hospital/ 
community), though this seems unlikely, as the (par-
tial) virus sequence of both cases was nearly identical. 
The resemblance in strain sequence between the Dutch 
cases and the case from the US is remarkable as the 
cases did not visit the same places in the Kingdom of 
Saudi Arabia. Exchange of information between the US 
Centers for Disease Control and Prevention and Dutch 
experts did not reveal any clues about mutual exposure 
of the Dutch and US cases. The current, limited scien-
tific information does not support any conclusion on 
Figure 1
Timeline of events for two MERS-CoV patients returning to the Netherlands from Saudi Arabia, May 2014
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the meaning of this genetic resemblance, knowing that 
multiple lineages of the virus can be found in camels 
and people [2,12]. Continued vigilance in evaluation of 
contacts of imported cases, including molecular test-
ing and serology, will hopefully lead to better insights. 
The public health response to these two imported 
cases was in line with the procedures put in place in 
the Netherlands [4,13]. Healthcare professionals in the 
Netherlands have been made aware of MERS-CoV since 
its emergence in 2012. MERS-CoV laboratory testing 
protocols have been implemented, including 24-hour 
availability of parallel testing in two separate labora-
tories if suspected cases are identified. These prepa-
rations facilitated the rapid follow-up and diagnosis of 
Case 2. 
A national outbreak investigation team was formed of 
clinicians, medical virologists, public health special-
ists, epidemiologists, staff members from the national 
response unit and a press officer. This team convened 
in a nearly daily teleconference to (i) share new devel-
opments regarding the cases, their laboratory follow-
up  and case histories; (ii) to perform a structured 
assessment of the public health risks for the contacts; 
(iii) perform risk classification of contacts; (iv) issue 
guidelines for follow-up; (v) provide information to pro-
fessionals and the media; and (vi) monitor progression 
of the response [13].
 Immediately after the diagnosis was confirmed in Case 
1, on 14 May, a press release was issued, followed by 
regular updates to emphasise the control measures 
designed to prevent secondary transmission. The 
World Health Organization was notified according 
to the International Health Regulations (IHR) by the 
National Focal Point, and international warnings were 
issued through the European Union Early Warning and 
Response System. The IHR Focal Point of the Kingdom 
of Saudi Arabia was notified as well.
Finally, updated guidelines for case finding, laboratory 
diagnosis, contact investigation and monitoring and 
infection control were revised and disseminated to the 
health professionals in the Netherlands using an elec-
tronic alerting system. 
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Table 
Real-time reverse transcription-PCR results from two 
MERS-CoV patients returning to the Netherlands from 
Saudi Arabia, May 2014
Day of 
samplinga
Throat 
swabb Serum
b Faecesb Urineb
Case 1
D0 31.3/31.5 – – –
D4 29.6/27.2 34.0/30.3 – ND/ND
D5 34.6/34.2 33.6/31.0 34.6/33.5 –
D6 33.5/31.6 33.7/31.7 – ND/ND
D7 ND/ND 35.9/33.4 ND/ND ND/ND
D8 ND/ND 38.3/35.8 ND/ND ND/ND
D9 37.8/34.9 ND/37.6 – ND/ND
Case 2
D0 34.5/32.5 – ND/ND –
D1 – 35.5/33.6 38.8/ND –
D2 – 34.6/36.4 ND/ND –
D3 – 37.4/38.6 ND/38.4 ND/ND
D4 – 37.8/36.7 38.7/ND ND/ND
D5 – 36.0/38.3 – ND/ND
Dashes show where no samples were available.
MERS-CoV: Middle East respiratory syndrome coronavirus; ND: not 
detected.
a Time of sampling starts from the date of diagnosis (D0).
b Threshold cycle (Ct) values of MERS-CoV upE PCR/Ct values of 
N-gene reverse transcription-PCR. 
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